JDRF Blog

Latest in Immune Therapies

  • Updates from the Teplizumab Trial: You’re Not Going to Believe the Results

    June 15, 2020

    Last year, at the American Association for Diabetes (ADA) Scientific Sessions, a drug, called teplizumab, was able to significantly delay—for over two...

  • Dr. Carla Greenbaum Talks about T1D TrialNet During the COVID-19 Pandemic

    May 7, 2020

    Carla Greenbaum, M.D., chair of TrialNet—an international JDRF-supported network that is dedicated to finding cures for type 1 diabetes (T1D)—and a professor...

  • New Research Suggests that T1D Has Two Distinct Types

    April 1, 2020

    JDRF-funded researchers found that type 1 diabetes is comprised of two different subtypes, called endotypes, which are dependent upon the age at diagnosis.

  • Why Does One Scientist Seek Cures for T1D? Answer: Family

    December 3, 2019

    Reza Abdi, M.D., has a reason to care about diabetes research—he has a father and a brother with the disease. Dr. Abdi,...

  • FDA Breakthrough Therapy Designation for Teplizumab—Based on the First Study to Delay the Onset of T1D for 2+ Years

    August 5, 2019

    The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to teplizumab, an anti-CD3 monoclonal antibody, for the prevention or delay...

  • ADA Scientific Sessions Recap—Day #4: Simi Ahmed, Ph.D.

    June 11, 2019

    The American Diabetes Association’s Scientific Sessions is almost coming to a close! Here is Simi Ahmed, Ph.D., head of the immune therapy...

  • First Human Study to Significantly Delay—by Two Years!—Type 1 Diabetes Onset

    June 9, 2019

    This is big. No, wait, this is ENORMOUSLY HUGE. Published today in the New England Journal of Medicine, an immune therapy demonstrated...

  • Your Cancer is Gone; Type 1 Diabetes is Here

    May 31, 2019

    Immune therapy has transformed cancer care. In some cases, cancer is effectively cured in people with stage 4 disease. But it has...